Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POSFREA.
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole selectively inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
200-400 mg IV once daily; for candidemia or invasive candidiasis, loading dose of 800 mg IV on day 1, then 400 mg IV once daily.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Terminal elimination half-life approximately 30 hours (range 20-50 hours). Prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min).
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 80% unchanged drug; feces: 11%; biliary: minor.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category A/B
Category C
Azole Antifungal
Azole Antifungal